Skip to main content

Table 3 Maspin expression in bladder cancer

From: Role of maspin in cancer

Authors Years N. patients Maspin expression Clinical features/prognosis
Acikalin et al. 2012 68 (T1 bladder cancer) Not specified Positive maspin = longer PFS and less recurrence
     Negative maspin = shorter PFS and more recurrence
Kramer at al. 2010 162 (pTa-pT1 bladder cancer) 75.9% positive maspin Positive maspin = PFS: 46 months
    24.1% negative maspin Negative maspin = PFS: 18 months
Friedrich et al. 2004 110 (pTa-pT1 bladder cancer) 33.6% positive maspin Positive maspin = PFS: 29 months, MVD: 17.7(CD34) and 6.0 (CD105)per field
    66.4%negative maspin Negative maspin = PFS: 23 months, MVD = 21.7 (CD34) and 4.2 (CD105)per field
Sugimoto et al. 2004 65 (22 transurethral resection and 43 radical resection specimens) 18.2%positive maspin in transurethral resection specimens Positive maspin = progression from invasive bladder cancer
    51.2% positive maspin in radical resection specimens  
Nehad et al. 2010 134 (56 squamous cell carcinoma (scc)and 78 transitional urinary bladder(tcc)) 53.7% positive maspin (42.8% scc and 61.5% tcc) Positive maspin = 91.7% low grade
    46.3% negative maspin Negative maspin = 54.8% high grade
Blandamura et al. 2008 66 (48 pTa e 18 pT1) 38% positive maspin 60.5% positive maspin have high grade
    62% negative maspin 22.44% positive maspin have low grade